AU2018254429A1 - VMAT2 inhibitor compounds and compositions thereof - Google Patents
VMAT2 inhibitor compounds and compositions thereof Download PDFInfo
- Publication number
- AU2018254429A1 AU2018254429A1 AU2018254429A AU2018254429A AU2018254429A1 AU 2018254429 A1 AU2018254429 A1 AU 2018254429A1 AU 2018254429 A AU2018254429 A AU 2018254429A AU 2018254429 A AU2018254429 A AU 2018254429A AU 2018254429 A1 AU2018254429 A1 AU 2018254429A1
- Authority
- AU
- Australia
- Prior art keywords
- compound
- isoquinoline
- methyl
- pharmaceutically acceptable
- disorder
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 0 CC(C)C[C@]1N(C)C[C@](c(c(CC2)c3)cc(OC)c3O*)N2C1 Chemical compound CC(C)C[C@]1N(C)C[C@](c(c(CC2)c3)cc(OC)c3O*)N2C1 0.000 description 6
- MMVBNZXJQWBYPE-GDBMZVCRSA-N CC(C)(C)C[C@H]1N(C)C[C@H](c(c(CC2)c3)cc(OC)c3O)N2C1 Chemical compound CC(C)(C)C[C@H]1N(C)C[C@H](c(c(CC2)c3)cc(OC)c3O)N2C1 MMVBNZXJQWBYPE-GDBMZVCRSA-N 0.000 description 2
- SJTKIXVAGORCNT-GFCCVEGCSA-N CC(C)C[C@H](C(NCCc(cc1O)ccc1OC)=O)N Chemical compound CC(C)C[C@H](C(NCCc(cc1O)ccc1OC)=O)N SJTKIXVAGORCNT-GFCCVEGCSA-N 0.000 description 1
- OFCMPOFLSVHIKH-OAHLLOKOSA-N CC(C)C[C@H](C(NCCc(cc1O)ccc1OC)=O)NCC(OC)OC Chemical compound CC(C)C[C@H](C(NCCc(cc1O)ccc1OC)=O)NCC(OC)OC OFCMPOFLSVHIKH-OAHLLOKOSA-N 0.000 description 1
- ZXDJRVPJHXDWDS-GDBMZVCRSA-N CC(C)C[C@H]1N(C)C[C@H](c(c(CC2)c3)cc(OC)c3O)N2C1 Chemical compound CC(C)C[C@H]1N(C)C[C@H](c(c(CC2)c3)cc(OC)c3O)N2C1 ZXDJRVPJHXDWDS-GDBMZVCRSA-N 0.000 description 1
- KXFVVBZQDBRNGP-ZIAGYGMSSA-N CC(C)C[C@H]1NC[C@H](c(cc2OC)c(CC3)cc2O)N3C1=O Chemical compound CC(C)C[C@H]1NC[C@H](c(cc2OC)c(CC3)cc2O)N3C1=O KXFVVBZQDBRNGP-ZIAGYGMSSA-N 0.000 description 1
- NUMUTRZZVHYJEB-HUUCEWRRSA-N COc(cc([C@@H](CN[C@@H]1CC2CCC2)N(CC2)C1=O)c2c1)c1O Chemical compound COc(cc([C@@H](CN[C@@H]1CC2CCC2)N(CC2)C1=O)c2c1)c1O NUMUTRZZVHYJEB-HUUCEWRRSA-N 0.000 description 1
- WJXQFVMTIGJBFX-UHFFFAOYSA-N COc(ccc(CCN)c1)c1O Chemical compound COc(ccc(CCN)c1)c1O WJXQFVMTIGJBFX-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762487413P | 2017-04-19 | 2017-04-19 | |
| US62/487,413 | 2017-04-19 | ||
| US201862652837P | 2018-04-04 | 2018-04-04 | |
| US62/652,837 | 2018-04-04 | ||
| PCT/US2018/028031 WO2018195121A1 (en) | 2017-04-19 | 2018-04-17 | Vmat2 inhibitor compounds and compositions thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AU2018254429A1 true AU2018254429A1 (en) | 2019-11-07 |
Family
ID=62111264
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2018254429A Abandoned AU2018254429A1 (en) | 2017-04-19 | 2018-04-17 | VMAT2 inhibitor compounds and compositions thereof |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US11040970B2 (enExample) |
| EP (1) | EP3612532B1 (enExample) |
| JP (1) | JP7170662B2 (enExample) |
| KR (1) | KR20190140968A (enExample) |
| CN (1) | CN110770236B (enExample) |
| AU (1) | AU2018254429A1 (enExample) |
| BR (1) | BR112019021853A2 (enExample) |
| CA (1) | CA3060251A1 (enExample) |
| CL (1) | CL2019002919A1 (enExample) |
| CO (1) | CO2019011604A2 (enExample) |
| ES (1) | ES2971230T3 (enExample) |
| JO (1) | JOP20190239A1 (enExample) |
| MA (1) | MA50145A (enExample) |
| MX (1) | MX2019012336A (enExample) |
| PE (1) | PE20191784A1 (enExample) |
| TW (1) | TW201841913A (enExample) |
| WO (1) | WO2018195121A1 (enExample) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MY199695A (en) | 2017-01-27 | 2023-11-18 | Neurocrine Biosciences Inc | Methods for the administration of certain vmat2 inhibitors |
| PT3684333T (pt) | 2017-09-21 | 2025-05-08 | Neurocrine Biosciences Inc | Formulações e composições de valbenazina de alta dosagem, métodos, e kits relacionados com as mesmas |
| MX2020003421A (es) | 2017-10-10 | 2020-07-20 | Neurocrine Biosciences Inc | Metodos para la administracion de ciertos inhibidores del transportador vesicular de monoamina 2 (vmat2). |
| WO2019241555A1 (en) * | 2018-06-14 | 2019-12-19 | Neurocrine Biosciences, Inc. | Vmat2 inhibitor compounds, compositions, and methods relating thereto |
| MX2021001017A (es) | 2018-08-15 | 2021-04-19 | Neurocrine Biosciences Inc | Metodos para la administracion de ciertos inhibidores de transportador vesicular de monoamina de proteinas transportadoras-2 (vmat2). |
| TW202033521A (zh) * | 2018-10-24 | 2020-09-16 | 美商紐羅克里生物科學有限公司 | 製備囊泡單胺轉運蛋白2(vmat2)抑制劑之方法 |
| PH12022550754A1 (en) | 2019-09-30 | 2023-08-23 | Incyte Corp | Pyrido[3,2-d]pyrimidine compounds as immunomodulators |
| AU2020385113A1 (en) | 2019-11-11 | 2022-05-19 | Incyte Corporation | Salts and crystalline forms of a PD-1/PD-L1 inhibitor |
| MX2023010566A (es) | 2021-03-22 | 2023-09-21 | Neurocrine Biosciences Inc | Inhibidores de proteina transportadora vesicular monoaminotransportadora-2 (vmat2) y metodos de uso. |
| WO2022232380A1 (en) | 2021-04-29 | 2022-11-03 | Neurocrine Biosciences, Inc. | Processes for preparing a vmat2 inhibitor |
| CA3229341A1 (en) | 2021-08-20 | 2023-02-23 | Ryan TERRY-LORENZO | Methods of screening for vmat2 inhibitors |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5798119A (en) | 1995-06-13 | 1998-08-25 | S. C. Johnson & Son, Inc. | Osmotic-delivery devices having vapor-permeable coatings |
| GB0106177D0 (en) | 2001-03-13 | 2001-05-02 | Hoffmann La Roche | Piperazine derivatives |
| AU2004251829B2 (en) | 2003-06-20 | 2009-12-17 | F. Hoffmann-La Roche Ag | Hexahydropyridoisoqinolines as DPP-IV inhibitors |
| US20060035883A1 (en) * | 2004-08-13 | 2006-02-16 | Tedford Clark E | Novel serotonin receptor ligands and their uses thereof |
| CN101553487B (zh) | 2006-11-08 | 2012-06-13 | 纽罗克里生物科学有限公司 | 取代的3-异丁基-9,10-二甲氧基-1,3,4,6,7,11b-六氢-2H-吡啶并[2,1-a]异喹啉-2-醇化合物和与其相关的方法 |
| FR2912145B1 (fr) | 2007-02-02 | 2009-03-06 | Servier Lab | Nouveaux derives tricycliques,leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
| US9012471B2 (en) * | 2008-04-11 | 2015-04-21 | The Trustees Of Columbia University In The City Of New York | Glucose metabolism modulating compounds |
| EP3345905B1 (en) | 2008-09-18 | 2021-09-01 | Auspex Pharmaceuticals, Inc. | Deuterated benzoquinolizine derivatives as inhibitors of vesicular monoamine transporter 2 |
| US8772301B2 (en) * | 2009-12-18 | 2014-07-08 | Sunovion Pharmaceuticals, Inc. | Compounds for treating disorders mediated by metabotropic glutamate receptor 5, and methods of use thereof |
| CN102285984B (zh) * | 2010-11-25 | 2012-10-10 | 江苏威凯尔医药科技有限公司 | (2R,3R,11bR)-二氢丁苯那嗪及相关化合物的制备方法 |
| WO2014043866A1 (zh) | 2012-09-19 | 2014-03-27 | 中国科学院福建物质结构研究所 | 噻吩[2,3-d]嘧啶衍生物、其制备方法及其用途 |
| WO2015120317A1 (en) | 2014-02-07 | 2015-08-13 | Neurocrine Biosciences, Inc. | Pharmaceutical compositions comprising an antipsychotic drug and a vmat2 inhibitor and uses thereof |
| EP3253752B1 (en) * | 2015-02-06 | 2023-08-16 | Neurocrine Biosciences, Inc. | [9,10-dimethoxy-3-(2-methylpropyl)-1h,2h,3h,4h,6h,7h,11bh-pyrido-[2,1-a]isoquinolin-2-yl]methanol and compounds, compositions and methods relating thereto |
| PT3558990T (pt) | 2016-12-22 | 2022-11-21 | Incyte Corp | Derivados de tetrahidroimidazo[4,5-c]piridina como indutores da internalização de pd-l1 |
| BR112019012993A2 (pt) | 2016-12-22 | 2019-12-03 | Incyte Corporation | derivados de benzo-oxazol como imunomoduladores |
-
2017
- 2017-06-16 JO JOP/2019/0239A patent/JOP20190239A1/ar unknown
-
2018
- 2018-04-17 WO PCT/US2018/028031 patent/WO2018195121A1/en not_active Ceased
- 2018-04-17 US US16/606,191 patent/US11040970B2/en active Active
- 2018-04-17 MA MA050145A patent/MA50145A/fr unknown
- 2018-04-17 EP EP18722357.3A patent/EP3612532B1/en active Active
- 2018-04-17 CN CN201880040884.XA patent/CN110770236B/zh active Active
- 2018-04-17 ES ES18722357T patent/ES2971230T3/es active Active
- 2018-04-17 PE PE2019002077A patent/PE20191784A1/es unknown
- 2018-04-17 KR KR1020197033620A patent/KR20190140968A/ko not_active Withdrawn
- 2018-04-17 JP JP2019556587A patent/JP7170662B2/ja active Active
- 2018-04-17 AU AU2018254429A patent/AU2018254429A1/en not_active Abandoned
- 2018-04-17 CA CA3060251A patent/CA3060251A1/en active Pending
- 2018-04-17 MX MX2019012336A patent/MX2019012336A/es unknown
- 2018-04-17 TW TW107112964A patent/TW201841913A/zh unknown
- 2018-04-17 BR BR112019021853-0A patent/BR112019021853A2/pt not_active Application Discontinuation
-
2019
- 2019-10-14 CL CL2019002919A patent/CL2019002919A1/es unknown
- 2019-10-18 CO CO2019011604A patent/CO2019011604A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| US20200131173A1 (en) | 2020-04-30 |
| MA50145A (fr) | 2020-07-29 |
| JP2020517607A (ja) | 2020-06-18 |
| BR112019021853A2 (pt) | 2020-05-26 |
| CO2019011604A2 (es) | 2019-10-31 |
| WO2018195121A1 (en) | 2018-10-25 |
| US11040970B2 (en) | 2021-06-22 |
| EP3612532A1 (en) | 2020-02-26 |
| CN110770236A (zh) | 2020-02-07 |
| MX2019012336A (es) | 2020-07-14 |
| JP7170662B2 (ja) | 2022-11-14 |
| JOP20190239A1 (ar) | 2019-10-09 |
| CL2019002919A1 (es) | 2020-01-17 |
| TW201841913A (zh) | 2018-12-01 |
| ES2971230T3 (es) | 2024-06-04 |
| KR20190140968A (ko) | 2019-12-20 |
| CN110770236B (zh) | 2023-03-24 |
| EP3612532C0 (en) | 2023-12-13 |
| PE20191784A1 (es) | 2019-12-24 |
| EP3612532B1 (en) | 2023-12-13 |
| CA3060251A1 (en) | 2018-10-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP3612532B1 (en) | Vmat2 inhibitor compounds and compositions thereof | |
| JP7155206B2 (ja) | 神経学的疾患または障害を処置するためのｖｍａｔ２阻害剤 | |
| JP2024114905A (ja) | Ｖｍａｔ２インヒビター化合物、上記化合物に関する組成物および方法 | |
| KR20190108146A (ko) | 특정 vmat2 억제제의 투여 방법 | |
| US20200078352A1 (en) | Use of Valbenazine for Treating Schizophrenia or Schizoaffective Disorder | |
| HK1248116B (en) | Vmat2 inhibitors for treating neurological diseases or disorders | |
| BR112017027839B1 (pt) | Uso de inibidores de vmat2 para preparação de uma composição farmacêutica para tratar mania em um transtorno de humor em um indivíduo; e/ou tratar transtorno obsessivo-compulsivo (toc) refratário ao tratamento | |
| JP2025532595A (ja) | グリコーゲンシンターゼ１（ｇｙｓ１）の阻害剤としてのｎ－（ベンズヒドリル）シクロアルキルカルボキサミド誘導体及びその使用方法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MK1 | Application lapsed section 142(2)(a) - no request for examination in relevant period |